Talk:Jeffrey Leiden: Difference between revisions

Content deleted Content added

Inline

Revision as of 13:11, 16 May 2022

This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.

If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page.

Biography Unassessed

	Biography portal This article is within the scope of WikiProject Biography, a collaborative effort to create, develop and organize Wikipedia's articles about people. All interested editors are invited to join the project and contribute to the discussion. For instructions on how to use this banner, please refer to the documentation.BiographyWikipedia:WikiProject BiographyTemplate:WikiProject Biographybiography articles
???	This article has not yet received a rating on Wikipedia's content assessment scale.

The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.

JohnDatVertex (talk · contribs) has been paid by Vertex Pharmaceuticals on behalf of Jeffrey Leiden.

Edit request to update the Vertex section

It is requested that an edit be made to the semi-protected article at A. (edit · history · last · links · protection log)

This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".

The edit may be made by any autoconfirmed user. Remember to change the |answered=no parameter to "yes" when the request has been accepted, rejected or on hold awaiting user input. This is so that inactive or completed requests don't needlessly fill up the edit requests category. You may also wish to use the {{ESp}} template in the response. To request that a page be protected or unprotected, make a protection request.

Hi. I am John and I would like to request some updates to Jeffrey Leiden's article.

Please add the following sentence as a new paragraph in the correct chronological order in the Vertex section, after the sentence that begins "In 2015 Vertex shareholders..." "The 2019 acquisition of Semma Therapeutics led to VX-880, the first potentially curative stem cell-based therapy for patients with type 1 diabetes.^[1]^[2]

At the end of the sentence that begins "On October 24, 2019, Vertex reached..." please remove Scotland and Spain and replace with Ireland^[3] and [[France]^[4], among others.

Also in the Vertex section, please add the following as a new paragraph below the sentence that begins "On October 24, 2019, Vertex reached an agreement..." "While Leiden served as chairman, the market capitalization of Vertex Pharmaceuticals increased from $7.74 billion at the beginning of 2012 to $69.97 billion in April 2020.^[5]^[6]

In the last paragraph of the Vertex section, please change April 2023 to April 2024.^[7]

References

^ Gelman, Max (29 January 2021). "The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic". Endpoints News.
^ Bell, Jacob (10 March 2021). "Vertex begins human testing for diabetes cell therapy". BiopharmaDive.
^ "Landmark NHS deal to open up access to life-changing cystic fibrosis drug". EnglandNHS. 21 August 2020.
^ Bruce, Francesca (15 July 2021). "Vertex Inks New Cystic Fibrosis Deals In Europe". Pink Sheet.
^ "VRTX Market Cap History". Market Cap History. 31 January 2022.
^ "Market capitalization of Vertex Pharmaceuticals (VRTX)". Companies Market Cap. 31 March 2022.
^ "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 10-K". investors.vrtx.com. SEC.

Thank you for your help, JohnDatVertex (talk) 17:43, 1 April 2022 (UTC)[reply]

Partially done, as the sources provided for #1 said no such thing, and I'm not sure about the reliability of #2's. PK650 (talk) 07:45, 3 April 2022 (UTC)[reply]

I am marking this request as answered, per the above. Z1720 (talk) 14:36, 5 April 2022 (UTC)[reply]

Hi PK650. Thanks for helping out with the above edits. I have re-written the sentence for the first edit that you declined above in a way that more precisely reflects the sources supplied. Please add the following as a new paragraph after the sentence that begins "In 2015 Vertex shareholders..." "Also under his leadership, Vertex acquired Semma Therapeutics for $950 million in 2019. The company developed stem cell-derived therapies including the experimental cell therapy for Type 1 diabetes known as VX-880. ^[1]^[2]"

References

^ Gelman, Max (29 January 2021). "The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic". Endpoints News.
^ Bell, Jacob (10 March 2021). "Vertex begins human testing for diabetes cell therapy". BiopharmaDive.

Thanks so much. JohnDatVertex (talk) 13:10, 16 May 2022 (UTC)[reply]

[Endpoints_News:The_diabetes_cure-1] Gelman, Max (29 January 2021). "The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic". Endpoints News.

[BiopharmaDive:Vertex_begins_human_testing-2] Bell, Jacob (10 March 2021). "Vertex begins human testing for diabetes cell therapy". BiopharmaDive.

[EnglandNHS:Landmark_NHS_deal-3] "Landmark NHS deal to open up access to life-changing cystic fibrosis drug". EnglandNHS. 21 August 2020.

[Pink_Sheet:Vertex_Inks-4] Bruce, Francesca (15 July 2021). "Vertex Inks New Cystic Fibrosis Deals In Europe". Pink Sheet.

[Market_Cap_History:Vertex-5] "VRTX Market Cap History". Market Cap History. 31 January 2022.

[Companies_Market_Cap:Vertex-6] "Market capitalization of Vertex Pharmaceuticals (VRTX)". Companies Market Cap. 31 March 2022.

[SEC:Form_10-K-7] "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 10-K". investors.vrtx.com. SEC.

[Endpoints_News:The_diabetes_cure-8] Gelman, Max (29 January 2021). "The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic". Endpoints News.

[BiopharmaDive:Vertex_begins_human_testing-9] Bell, Jacob (10 March 2021). "Vertex begins human testing for diabetes cell therapy". BiopharmaDive.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[1]

[2]

@@ Line 19: / Line 19: @@
 :{{tick}} Partially done, as the sources provided for #1 said no such thing, and I'm not sure about the reliability of #2's. [[User:PK650|PK650]] ([[User talk:PK650|talk]]) 07:45, 3 April 2022 (UTC)
 ::I am marking this request as answered, per the above. [[User:Z1720|Z1720]] ([[User talk:Z1720|talk]]) 14:36, 5 April 2022 (UTC)
+:::Hi {{u|PK650}}. Thanks for helping out with the above edits. I have re-written the sentence for the first edit that you declined above in a way that more precisely reflects the sources supplied. Please add the following as a new paragraph after the sentence that begins "In 2015 Vertex shareholders..." "Also under his leadership, Vertex acquired Semma Therapeutics for $950 million in 2019. The company developed stem cell-derived therapies including the experimental cell therapy for Type 1 diabetes known as VX-880. <ref name="Endpoints News:The diabetes cure">{{cite news |last1=Gelman |first1=Max |title=The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic |url=https://endpts.com/the-diabetes-cure-vertex-acquired-in-its-2019-semma-buyout-its-headed-to-the-clinic/ |publisher=Endpoints News |date=29 January 2021}}</ref><ref name="BiopharmaDive:Vertex begins human testing">{{cite news |last1=Bell |first1=Jacob |title=Vertex begins human testing for diabetes cell therapy |url=https://www.biopharmadive.com/news/vertex-semma-human-testing-diabetes-cell-therapy/596466/ |publisher=BiopharmaDive |date=10 March 2021}}</ref>"
+{{reflist-talk}}
+:::Thanks so much. [[User:JohnDatVertex|JohnDatVertex]] ([[User talk:JohnDatVertex|talk]]) 13:10, 16 May 2022 (UTC)